See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Natural Disasters
Trade War
Donald Trump
Social Media
Baseball
Stock Markets
Artificial Intelligence
Education
Soccer
Trade
Property
Published • loading... • Updated

Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer

Summary by urologytime.com
"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
urologytime.comurologytime.com

Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

urologytime.com broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal